In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report), with a price target of $4.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors including promising preclinical data and potential future developments. Kairos Pharma recently announced positive results for their novel GITR agonist, KROS101, which showed enhanced T cell activity and reduced immunosuppression in melanoma and glioblastoma. This suggests a unique mechanism that could complement existing cancer treatments and positions KROS101 as a promising candidate in the oncology space.
Another key factor influencing the Buy rating is the anticipated interim data from the ongoing Phase 2 trial for ENV-105 in metastatic castration-resistant prostate cancer. If these results are positive, they could serve as a significant catalyst for the company’s stock. Additionally, the financial modeling considers future commercialization prospects and applies risk adjustments and discount rates to derive a 12-month price target, further supporting the Buy recommendation.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of -19.8% and a 27.56% success rate on recommended stocks.